Free Trial

Generation Bio (GBIO) Competitors

Generation Bio logo
$6.14 -0.28 (-4.29%)
As of 03:26 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

GBIO vs. ELDN, CCCC, THTX, PEPG, MOLN, NKTX, ANRO, NVCT, CRDF, and ACOG

Should you be buying Generation Bio stock or one of its competitors? The main competitors of Generation Bio include Eledon Pharmaceuticals (ELDN), C4 Therapeutics (CCCC), Theratechnologies (THTX), PepGen (PEPG), Molecular Partners (MOLN), Nkarta (NKTX), Alto Neuroscience (ANRO), Nuvectis Pharma (NVCT), Cardiff Oncology (CRDF), and Alpha Cognition (ACOG). These companies are all part of the "pharmaceutical products" industry.

Generation Bio vs. Its Competitors

Generation Bio (NASDAQ:GBIO) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

Eledon Pharmaceuticals has lower revenue, but higher earnings than Generation Bio. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Generation Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Generation Bio$21.23M1.95-$131.67M-$10.82-0.57
Eledon PharmaceuticalsN/AN/A-$36.18M-$1.17-2.95

Generation Bio has a beta of 2.53, meaning that its share price is 153% more volatile than the S&P 500. Comparatively, Eledon Pharmaceuticals has a beta of 0.4, meaning that its share price is 60% less volatile than the S&P 500.

In the previous week, Eledon Pharmaceuticals had 2 more articles in the media than Generation Bio. MarketBeat recorded 2 mentions for Eledon Pharmaceuticals and 0 mentions for Generation Bio. Generation Bio's average media sentiment score of 0.00 beat Eledon Pharmaceuticals' score of -0.36 indicating that Generation Bio is being referred to more favorably in the media.

Company Overall Sentiment
Generation Bio Neutral
Eledon Pharmaceuticals Neutral

95.2% of Generation Bio shares are owned by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. 21.8% of Generation Bio shares are owned by insiders. Comparatively, 12.3% of Eledon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Eledon Pharmaceuticals has a net margin of 0.00% compared to Generation Bio's net margin of -341.12%. Generation Bio's return on equity of -91.07% beat Eledon Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Generation Bio-341.12% -91.07% -33.65%
Eledon Pharmaceuticals N/A -92.51%-38.31%

Generation Bio currently has a consensus target price of $10.67, indicating a potential upside of 73.87%. Eledon Pharmaceuticals has a consensus target price of $10.00, indicating a potential upside of 189.44%. Given Eledon Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Eledon Pharmaceuticals is more favorable than Generation Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Generation Bio
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Eledon Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

Summary

Generation Bio beats Eledon Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Get Generation Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for GBIO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GBIO vs. The Competition

MetricGeneration BioMED IndustryMedical SectorNASDAQ Exchange
Market Cap$41.32M$3.41B$6.22B$10.49B
Dividend YieldN/A2.27%5.74%4.88%
P/E Ratio-0.5722.9428.6527.04
Price / Sales1.95425.29550.76162.85
Price / CashN/A46.4037.3861.65
Price / Book0.4810.4112.316.43
Net Income-$131.67M-$52.53M$3.33B$276.72M
7 Day Performance-8.57%-1.69%-1.74%-2.95%
1 Month Performance5.96%9.45%4.72%-0.09%
1 Year Performance-73.67%11.28%61.14%29.93%

Generation Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GBIO
Generation Bio
3.5756 of 5 stars
$6.14
-4.3%
$10.67
+73.9%
-71.4%$41.32M$21.23M-0.57150
ELDN
Eledon Pharmaceuticals
1.8003 of 5 stars
$2.72
-0.7%
$10.00
+267.6%
+15.2%$164.08MN/A-2.3210
CCCC
C4 Therapeutics
3.4811 of 5 stars
$2.11
-6.2%
$8.50
+302.8%
-60.6%$160.13M$35.58M-1.34150News Coverage
THTX
Theratechnologies
N/A$3.42
+0.9%
N/A+151.4%$157.21M$84.38M-17.99140High Trading Volume
PEPG
PepGen
3.195 of 5 stars
$4.55
-3.6%
$8.40
+84.6%
-44.0%$154.65MN/A-1.5430
MOLN
Molecular Partners
1.3736 of 5 stars
$3.87
+1.7%
$8.00
+107.0%
-45.4%$153.42M$5.65M-1.86180Positive News
Gap Up
NKTX
Nkarta
1.8967 of 5 stars
$2.26
+4.6%
$13.50
+497.3%
-43.4%$153.41MN/A-1.53140News Coverage
ANRO
Alto Neuroscience
1.5424 of 5 stars
$5.89
+4.5%
$9.80
+66.3%
-23.3%$152.71MN/A-2.47N/AAnalyst Forecast
Gap Down
NVCT
Nuvectis Pharma
2.612 of 5 stars
$6.19
+3.9%
$15.33
+147.7%
-21.7%$151.72MN/A-5.298
CRDF
Cardiff Oncology
1.8653 of 5 stars
$2.26
+2.3%
$10.63
+370.1%
-19.5%$147.02M$680K-2.6020News Coverage
ACOG
Alpha Cognition
2.5642 of 5 stars
$7.05
+0.4%
$20.00
+183.7%
N/A$146.73MN/A-4.41N/ATrending News
Analyst Forecast
Short Interest ↑
Analyst Revision

Related Companies and Tools


This page (NASDAQ:GBIO) was last updated on 10/22/2025 by MarketBeat.com Staff
From Our Partners